Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Melanoma and other skin tumours

5845 - Intratumoral (IT) Injection of the TLR9 agonist tilsotolimod (IMO-2125) in combination with ipilimumab (ipi) triggers durable responses in PD-1 inhibitor refractory metastatic melanoma (rMM): Results from a Multicenter, Phase 1/2 study

Date

20 Oct 2018

Session

Poster Discussion session - Melanoma and other skin tumours

Presenters

Adi Diab

Citation

Annals of Oncology (2018) 29 (suppl_8): viii442-viii466. 10.1093/annonc/mdy289

Authors

A. Diab1, C. Haymaker2, C. Bernatchez2, R.H.I. Andtbacka3, M. Shaheen4, D. Johnson5, J. Markowitz6, I. Puzanov7, R. Murthy8, D.H. Johnson1, M. James1, S. Chunduru9, J. Geib10, S. Swann11, S. Rahimian12, P. Hwu13

Author affiliations

  • 1 Melanoma, MD Anderson Cancer Center, 77030-4095 - Houston/US
  • 2 Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 77030 - Houston/US
  • 3 Surgical oncology, Huntsman Cancer Institute, 84112 - Salt Lake City/US
  • 4 Medicine, University of Arizona Cancer Center North, Tucson/US
  • 5 Medical Oncology, Vanderbilt University, Nashville/US
  • 6 Medical Oncology, Moffitt Cancer Center, Tampa/US
  • 7 Melanoma, Roswell Park Cancer Center, Buffalo/US
  • 8 Interventional Radiology, MD Anderson Cancer Center, Houston/US
  • 9 Translational Biology, Idera Pharmaceuticals, 19341 - Exton/US
  • 10 Oncology Clinical Development, Idera Pharmaceuticals, 19341 - Exton/US
  • 11 Biometrics, Idera Pharmaceuticals, Exton/US
  • 12 Oncology, Idera Pharmaceuticals, 19341 - Exton/US
  • 13 Melanoma, MD Anderson Cancer Center, 77030 - Houston/US
More

Resources

Abstract 5845

Background

Subsequent treatment with ipi offers 10-13% ORR (Bowyer 2016, Long 2016) in aPD1 refractory MM. Tilsotolimod, a synthetic TLR9 agonist oligonucleotide, acts on macrophages and dendritic cells to alter the tumor microenvironment. Local drug-induced type 1 interferon response results in increased antigen presentation and downstream T cell activation and proliferation in injected and non-injected lesions (Haymaker, SITC 2017).

Methods

The study will enroll up to 60 pts with rMM to receive IT (with/without IG) tilsotolimod (scheduled weeks 1,2,3,5,8,11,17, 23 and 29); ipi is given per the product label starting at week 2. Pts with M1c disease, mucosal melanoma and BRAF mutations were included. The primary endpoint is RECIST1.1 objective response rate (ORR); other endpoints are safety and tolerability and disease control rate (DCR). Immune analyses of T-cell repertoire diversity evaluated by high-throughput CDR3 sequencing. Phase 2 accrual is ongoing.

Results

As of 9 Apr 2018, 26 pts have been treated with tilsotolimod 8mg+ ipi, including 5 pts who received IG injections to deep visceral lesions or lymph nodes. Median age: 65.8 (range 39-91 yrs); 11 IVM1c. 6 pts had irAEs [hypophysitis (2), hepatitis (2), adrenal insufficiency (1), Guillain-Barre syndrome (1), colitis (1), enterocolitis (1)], which responded to standard measures. Injection-related toxicities were grade 1-2 transient fever and flu like symptoms lasting <48 hours. Major expanding T-cell clones are found to be shared in responding local and distant lesions indicating that reactivation is to a shared antigen in responding patients. As of 9 May 2018, 21 pts were assessed for response: 38% ORR and 71% DCR (2 CR, 6 PR, 7 SD). 6 of 8 responses are ongoing including 1 CR > 23 mo. 10 pts had BRAF mutations (1 CR, 3 PR, and 4 SD).

Conclusions

IT tilsotolimod 8mg+ ipi is well tolerated and shows substantial clinical benefit and durable responses. The ORR of 38% compares favorably to ipi in this challenging population, leading to an ongoing global randomized Phase 3 study of tilsotolimod 8mg+ipi vs. ipi in aPD-1 rMM.

Clinical trial identification

NCT02644967.

Legal entity responsible for the study

Idera Pharmaceuticals.

Funding

Idera Pharmaceuticals.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings